



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	1.89
Trade Time:	4:10 PM ET 08/23/17
Change:	0.06 ↑ (3.279%)
Day Range	1.79 - 1.95
52-Week Range	1.27 - 7.10
Volume	67,845

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 08/14/17**
[Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans](#)
- 08/07/17**
[Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results](#)
- 07/10/17**
[Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117](#)
- 06/07/17**
[Rexahn Announces \\$10 Million Registered Direct Offering](#)
- 06/04/17**
[Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- 02/24/17**
[Annual Report \(10-K\)](#)
- 02/24/17**
[Proxy Statement \(DEF 14A\)](#)
- 08/04/17**
[Quarterly Report \(10-Q\)](#)
- 05/03/17**
[Quarterly Report \(10-Q\)](#)
- 11/04/16**
[Quarterly Report \(10-Q\)](#)